1. 4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial. (September 2015) Authors: Choueiri, T.; Escudier, B.; Powles, T.; Mainwaring, P.; Rini, B.; Donskov, F.; Hammers, H.; Hutson, T.; Roth, B.; Peltola, K.; Lee, J.L.; Heng, D.; Schmidinger, M.; Borgman-Hagey, A.; Hessel, C.; Scheffold, C.; Schwab, G.; Tannir, N.; Motzer, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S708 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR). (February 2017) Authors: Schmidinger, M.; Motzer, R.J.; Powles, T.; Escudier, B.; Tannir, N.M.; Mainwaring, P.N.; Rini, B.I.; Hammers, H.J.; Donscov, F.; Roth, B.; Peltola, K.; Lee, J.L.; Heng, D.Y.C.; Aftab, D.T.; Hessel, C.; Scheffold, C.; Schwab, G.; Pal, S.; Hutson, T.E.; Choueiri, T.K. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile. (October 2020) Authors: Hsu, J.; Chong, C.; Goon, L.; Balayan, J.; Wu, S.; Johnson, E.; Lorenzana, G.; Bannen, L.; Nguyen, L.; Scheffold, C.; Lamb, P.; Xu, W.; Yu, P. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗